Earnings release
Page 1
Aker BioMarine ASA Date/time 31.10.2025, 06:00:00 MessageID 658400 IssuerID AKBM Instrument AKBM Market Oslo Børs Category HALF YEARLY FINANCIAL REPORTS AND AUDIT REPORTS / LIMITED REVIEWSAttachment Aker BioMarine Q3 2025 Presentation publish.pdf Share message Third quarter 2025 results for Aker BioMarine Highlights third quarter 2025: • Q3 revenue reached USD 56.8 million, a 15% increase year-over-year, with adjusted EBITDA of USD 12.2 million, up 50% from the prior year. • Human Health Ingredients delivered USD 30.2 million in revenue, up 23% YoY, driven by solid volume growth and improved price mix. Adjusted EBITDA grew 35% to USD 13.5 million. • Consumer Health Products generated USD 27.4 million in revenue, down 6% YoY, with stable EBITDA margins. • Emerging Business reported USD 2.0 million in revenue, stable compared to previous quarters. EBITDA improved from last year on lower opex. • Secured significant new business for the supply of Superba Krill Oil. “We continued our strong momentum in the third quarter, with 15% revenue growth and a 50% increase in adjusted EBITDA year-over-year. Human Health Ingredients again delivered good results, with strong demand across regions. Our ability to win new business further strengthens the outlook for this segment,” said Matts Johansen, CEO of Aker BioMarine. Segment performance Human Health Ingredients continued its strong trajectory with 23% revenue Mandatory noti cations OAM announcement Show advanced searchSearch issuer/ticker
Page 2
growth year-over-year, driven by both higher volumes and improved price mix. Adjusted EBITDA increased significantly, supported by solid gross margins and good operational leverage. During the quarter, the company secured a significant new supply agreement for Superba Krill Oil. Consumer Health Products reported a 6% decline in revenue year-over-year, mainly due to lower demand from drug stores. Demand has remained stable throughout 2025, albeit below the strong levels in the second half of 2024. EBITDA margin remained stable compared to last year as lower revenues was offset by improved gross margin. Outlook The Human Health Ingredients segment sees continued year-over-year growth, supported by good underlying demand in multiple markets. In Consumer Health Products, revenues are expected to follow market growth over time. The Emerging Business segment remains on track toward cash break-even, with active engagement in potential transactions. At the corporate level, the company has established a new, leaner cost base and is executing on initiatives to further improve financial and operational efficiency. AKBM is adapting to market trends through productivity and cost measures while actively assessing the potential impact of increased macroeconomic uncertainty and new tariffs. Attached is the quarterly presentation and report for Q3. Group reported financial figures can be downloaded in an excel from the company’s investor page: Investor - Analyst information At 09:00 CET today, the management hosts a webcast. The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor. A replay of the presentation will be made available soon after the presentation at the same web address. For further information, please contact Christopher Robin Vinter, VP Strategic Finance & IR Mobile: +47 911 60 820 Email: Christopher.vinter@akerbiomarine.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. About Aker BioMarine Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.